$19.20
5.26% today
Nasdaq, Aug 12, 10:00 pm CET
ISIN
IL0011407140
Symbol
URGN

UroGen Pharma Ltd. Stock price

$18.24
+4.00 28.09% 1M
+8.00 78.13% 6M
+7.59 71.27% YTD
+3.73 25.71% 1Y
+9.91 118.97% 3Y
-5.95 24.60% 5Y
+4.26 30.47% 10Y
+4.26 30.47% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.50 2.79%
ISIN
IL0011407140
Symbol
URGN
Industry

Key metrics

Basic
Market capitalization
$843.9m
Enterprise Value
$773.7m
Net debt
positive
Cash
$195.9m
Shares outstanding
42.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
9.2 | 6.7
EV/Sales
8.4 | 6.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-3.1%
Return on Equity
1,441.3%
ROCE
-52.5%
ROIC
-326.3%
Debt/Equity
-2.7
Financials (TTM | estimate)
Revenue
$91.9m | $126.4m
EBITDA
$-106.4m | $-126.9m
EBIT
$-108.0m | $-114.1m
Net Income
$-138.4m | $-125.5m
Free Cash Flow
$-107.4m
Growth (TTM | estimate)
Revenue
9.0% | 39.8%
EBITDA
-55.3% | -32.8%
EBIT
-55.9% | -17.9%
Net Income
-32.7% | 1.1%
Free Cash Flow
-30.2%
Margin (TTM | estimate)
Gross
89.7%
EBITDA
-115.8% | -100.4%
EBIT
-117.5%
Net
-150.7% | -99.3%
Free Cash Flow
-116.9%
More
EPS
$-2.9
FCF per Share
$-2.5
Short interest
16.0%
Employees
235
Rev per Employee
$380.0k
Show more

Is UroGen Pharma Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

UroGen Pharma Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a UroGen Pharma Ltd. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a UroGen Pharma Ltd. forecast:

Buy
86%
Hold
14%

Financial data from UroGen Pharma Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
92 92
9% 9%
100%
- Direct Costs 9.48 9.48
7% 7%
10%
82 82
9% 9%
90%
- Selling and Administrative Expenses 129 129
34% 34%
140%
- Research and Development Expense 62 62
27% 27%
67%
-106 -106
55% 55%
-116%
- Depreciation and Amortization 1.56 1.56
120% 120%
2%
EBIT (Operating Income) EBIT -108 -108
56% 56%
-118%
Net Profit -138 -138
33% 33%
-151%

In millions USD.

Don't miss a Thing! We will send you all news about UroGen Pharma Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

UroGen Pharma Ltd. Stock News

Neutral
Seeking Alpha
4 days ago
UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2025 Earnings Conference Call August 7, 2025 10:00 AM ET Company Participants Christopher Degnan - Chief Financial Officer David Lin - Chief Commercial Officer Elizabeth A.
Neutral
The Motley Fool
5 days ago
UroGen (URGN) Q2 Revenue Rises 11%
Neutral
GlobeNewsWire
5 days ago
ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) JELMYTO® achieved net product sales of $24.2 million in Q2 2025, compared with $21.8 million in Q2 2024, representing 11% year-over-year growth $161.6 million in cash, cash equivalents an...
More UroGen Pharma Ltd. News

Company Profile

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Head office Israel
CEO Elizabeth Barrett
Employees 235
Founded 2004
Website www.urogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today